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Volume 57, Number 5S Abstracts 79Sgrowth (as a proxy for rupture risk and the need for repair)
were examined.
Results: The average radiologic follow-up time was
22.0 6 13.6 months and the average aneurysm growth
rate was 2.8 6 1.7 mm/year. PWS in VWT models signiﬁ-
cantly differed from PWS in UWT models (238 6 68 vs
2126 73 kPa; P¼ .025). In our sample, initial aortic diam-
eter was not found to be correlated with aneurysm growth (r
¼ .26; P ¼ .19). A stronger correlation was found between
aneurysm growth and PWS derived from VWT models as
compared to PWS from UWT models (r ¼ .86 vs r ¼ .58;
P ¼ .032 by Fisher’s r to Z transformation; Fig).
Conclusions: The inclusion of locally variable wall
thickness signiﬁcantly improved the correlation between
PWS and aneurysm growth. Aortic wall thickness should
be incorporated into future FEA models to accurately
predict clinical outcomes.
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Objectives: Nitric oxide generated by endothelial
nitric oxide synthase (eNOS) acts at different levels to
sustain proper endothelial cell (EC) function. Pro-inﬂam-
matory molecules associated with various pathological
conditions negatively affect eNOS expression and activity,
altering vascular homeostasis. Decreased eNOS levels and
activity are the pathognomonic features of EC dysfunction
and a prelude to atherosclerotic remodeling of the vascula-
ture. We have demonstrated that A20 maintains EC
homeostasis by inhibiting NF-kappa B activation and pro-
tecting from apoptosis. The aim of this study is to explore
whether A20 impacts eNOS expression/activity.
Methods: A20 was overexpressed in human coronary
artery EC (HCAEC) by recombinant adenovirus-mediated
gene transfer. Effects of A20 on eNOS expression and
phosphorylation were analyzed by quantitative PCR,
human eNOS promoter-luciferase reporter assay, chro-
matin immunoprecipitation (ChIP) and Western blot.
Results: Our data demonstrate that over-expression of
A20 in HCAEC signiﬁcantly increased eNOS mRNA and
protein levels by promoting eNOS transcription, as demon-
strated by ChIP, and eNOS promoter analysis using
Luciferase reporter assays. Importantly, A20-induced upre-
gulation of eNOS expression was sustained in HCAEC
treated with tumor necrosis factor that inhibits eNOS tran-
scription and function.Moreover, A20 enhanced phosphory-
lation of eNOS (Ser-1177), a surrogate marker of its activity,
by promoting the activation of its upstream kinase AKT.
Conclusions: Our data demonstrate that A20 upregu-
lates and activates eNOS, even in EC exposed to inﬂamma-
tion. A20’s ability to promote and sustain eNOS activitycould be critical to its cytoprotective effect in EC. Further,
it supports our pursuit of A20-based therapies to maintain
vascular homeostasis, preventing vascular diseases such as
atherosclerosis, transplant arteriosclerosis and diabetic
vasculopathy.
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Objectives: Collaterals are an important determinant
of the capacity for compensation in occlusive disease. In
mice, advanced age (>16 months-age) is accompanied
by anatomic loss, or rarefaction, of native (pre-existing)
collaterals, resulting in worse ischemic injury. Targeted
deletion of eNOS greatly accelerates collateral loss, impli-
cating eNOS deﬁciency in age-associated collateral rare-
faction. To determine whether other CV risk factors in
addition to aging that are known to associate with
eNOS deﬁciency also cause collateral rarefaction, we
examined 7-8 months-old mice with hypertension (renin
transgene; MAP 139 6 3 mmHg) and other genetically
imposed CV risk factors.
Methods: Functional assessment of collateral capacity
in skeletal muscle was obtained by measurement of hin-
dlimb perfusion, limb use and ischemic appearance scores
after femoral artery ligation, and in brain by determining
infarct volume after middle cerebral artery occlusion.
Collateral extent (number and diameter) was determined
by ﬁlling the arterial circulation with a silicone-based
casting agent (Microﬁl).
Results: Hypertensive mice had greater reduction in
hindlimb ﬂow immediately after ligation (depends on
native collateral extent) and impaired recovery of perfusion
during 21 days thereafter (depends on native extent plus
collateral remodeling), worse ischemia and use impairment,
increased cerebral infarct volume, reduced native collateral
extent, and impaired collateral remodeling. Mice with
metabolic syndrome showed similar collateral rarefaction
and functional impairments. In contrast, hyperlipidemia,
type-1 diabetes and obesity were not accompanied by
collateral rarefaction.
Conclusions: Chronic hypertension leads to rarefac-
tion of the native collateral circulation and worse
ischemia and tissue necrosis following acute arterial
obstruction. Ongoing experiments are examining the
molecular mechanisms underlying hypertension-induced
collateral rarefaction.
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